Pancreatic cancer cells – image courtesy of the London Research Institute EM Unit

A recent publication in Clinical Cancer Research revealed some
ongoing pancreatic cancer research identifying key cancer biomarkers for developing laboratory tests
for early detection. Researchers have discovered three proteins that people with
pancreatic tumors continuously shed into the urine: LYVE-1, REG1A and
TFF1. The scientists at Bart’s Cancer
Institute in London who have been conducting these studies have sought to purse
these new markers in hopes to discover more reliable, accurate, and noninvasive
means to diagnose pancreatic cancer. Read More

Related Kits:

Cancer Biomarker


EagleBio’s Creatinine
Microplate Assay Kit Utilized in Two New Studies

EagleBio’s Creatinine
Microplate Assay Kit Used in Studying High Incidence of Lung Cancer in
Singapore Women

New Antibody–Drug
Conjugate (ADC) Study Utilizes Eagle Biosciences’ DM1 ADC ELISA Assay Kit

Could Polio be the Hero
in the Fight Against Cancer?

Using Bacterial Communication Systems to Combat Pancreatic
Cancer Cells

New “Tumor-in-a-Dish”
Technique May Improve Chemo

New Study Focuses On
Designing Novel Antibodies to Target Breast Cancer Cells